That may be too much to expect. I do not think you can predict another CR from the page 26 chart. Here is my reading from it.
Among 10 patients in Arm-A, only two patients had a tumor size less than 2 cm or T1a (tumor <2 cm and limited to the pancreas) and also likely were in stage 1A. Rest of 8 patients had tumor size between 2-7.5 cm. In cancer biology field, 1.0 CM(3) tumor has approximately 1 x 10(9) tumor cells. I believe that the CR occurred in one of 10 patients because the tumor burden in this patient is smaller, in its early clinical stage, and easier to be destroyed than those with huge tumor loads. In contrast, patient #6 has a tumor size of 6 cm which is a big tumor. It was quite dramatic when this 6 cm tumor shrank near to 3 cm with only a 3 months MTAA injection. Afterward, it is stabilized for a while. Actually, the response course of patient 6 is somewhat similar to patient #1. Another factor the company did not disclose is the histological types. There are 8 different types (ducal, mucinous, adenosquamous, signet-ring, neuroendocrine, acinar and others) of pancreatic cancer and each has different prognosis. I am assuming all 10 patients in the trial are pancreatic ductal carcinoma.
I do not know how long it will take for the antigen spread. But based on the chart on page 26, it definitely not occurred in all patients between 6-9 months. If you look at 3-6 months window after 3-month MTAA injection, 7/7 responded very well. That is 100% response rate compared only 50% response rate by conventional chemotherapy. However If you look at 6-9 months window, tumor size keeps shrinking in 2/5 patients, stabled in 1/5 patient, and enlarged in 2/5 patients. So we will see whether the response will hold for longer period time, say in 12-18 months. Regardless, the result of pancreatic cancer data is very robust and encouraging because the median survival is only 6.8 months even for stage 1A patients with pancreatic cancer.
News 
Market Data 
Discover 
AI
